公开(公告)号：WO2023086994A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079819

申请日：2022-11-14

Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

Inventor： OTTERBEIN, Leo E. ,  ALVES DE SOUZA, Rodrigo

IPC: G01N33/72 ,  A61K38/42 ,  C12Q1/28 ,  A61K33/26

Abstract: Disclosed herein are methods of assessing cellular or tissue damage in a patient; methods of identifying a patient having sterile inflammation, methods of assessing sterile inflammation in a patient, methods of monitoring a patient undergoing a treatment with a therapeutic agent that causes cellular or tissue toxicity, methods of treating or preventing cellular or tissue damage in a patient in need thereof, methods of treating or preventing sterile inflammation in a patient in need thereof, and related uses and kits.

公开(公告)号：WO2022258614A1

公开(公告)日：2022-12-15

申请号：PCT/EP2022/065398

申请日：2022-06-07

Applicant: CAMPBELL, Farida Hanna

Inventor： CAMPBELL, Farida Hanna

IPC: A23G4/12 ,  A61K33/26 ,  A61K36/064 ,  A61K38/17 ,  A61P31/12

Abstract: The present invention relates to a method for a chewing-gum based mitigation of virus-related disease spread and pre-immunity activation based on disruption of syntrophic methanogenic processes in the oral-, shared oronasal and orotracheal microbiome. The invention provides a chewing gum composition comprising a methylotrophic yeast, preferably Komagatella phaffii; a plant lectin, preferably phytohaemagglutinin; and/or iron particles, preferably zero-valent iron particles.

公开(公告)号：WO2022150623A1

公开(公告)日：2022-07-14

申请号：PCT/US2022/011668

申请日：2022-01-07

Applicant: AKEBIA THERAPEUTICS, INC.

Inventor： WEST, Kip ,  RABINOWITZ, Michael ,  ZUK, Anna ,  CHAVAN, Ajit ,  BURKE, Steven

IPC: A61K31/437 ,  A61K31/4412 ,  A61K31/4704 ,  A61K31/472 ,  A61K31/506 ,  A61K31/513 ,  A61K33/26 ,  A61P7/06 ,  A61P9/10 ,  A61P29/00

Abstract: Provided herein are therapeutic methods comprising administering a compound (e.g., a first compound) that is a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor in combination with a compound (e.g., a second compound) that is an iron- containing composition. In particular, methods described herein can result in improved (e.g., synergistic) therapeutic effects, and therefore can be useful for treating, preventing, regulating, and/or controlling a disease or condition (e.g., a disease or condition as described herein) in patients in need thereof.

公开(公告)号：WO2022112430A1

公开(公告)日：2022-06-02

申请号：PCT/EP2021/083029

申请日：2021-11-25

Applicant: PHOXBIO LIMITED

Inventor： MASOOD, Mohammed Abid ,  UPPAL, Rakesh ,  RUSSELL, Angela ,  SILPA, Laurence

IPC: A41D13/11 ,  A61K31/133 ,  A61K31/185 ,  A61K31/495 ,  A61K31/5375 ,  A61K33/10 ,  A61K33/26 ,  A61K33/30 ,  A61K38/40 ,  A61K31/05 ,  A61P31/12 ,  A61P31/14 ,  A61K36/53 ,  A61K36/61 ,  A61K36/9068

Abstract: The present invention relates to a composition comprising one or more of clove oil, eucalyptus oil, basil oil, ginger oil, an extract or component of any of these, or a combination thereof, and to a buffer composition having a pH of from 6.7 to 7.9 at a temperature of 37°C, both for use in the treatment, prophylactic treatment or amelioration of an airborne viral infection, or for use in reducing viral replication in a subject infected with an airborne virus or exposed to an airborne virus capable of causing an airborne viral infection in the subject. The present invention also relates to an aqueous composition either comprising a buffer and an essential oil with antiviral, antibacterial or antifungal activity; or comprising a buffer, hydrogen carbonate ions, and zinc ions; or comprising a buffer, hydrogen carbonate ions, and transferrin and/or iron ions. The present invention also relates to methods of preparing the compositions, and to concentrates of the compositions. The compositions can be used in a method of treatment, prophylactic treatment or amelioration of an airborne viral infection in a subject, and a method of reducing viral replication in a subject infected with an airborne virus or exposed to an airborne virus capable of causing an airborne viral infection in the subject. Airborne viruses include RNA viruses, such as coronaviruses, such as MERS-CoV, SARS-CoV, and SARS-C0V-2. The compositions can be administered by nasal spray, inhaler or nebulizer, or in the form of a cream, gel or emulsion, and the invention therefore also relates to nasal sprays, inhalers, nebulizers, creams, gels or emulsions comprising the compositions. The compositions can also be applied to a mask or other face covering thereby reducing the risk of viral infection with an airborne virus, and the invention therefore also relates to sprays comprising the compositions. The compositions can also be used in a receptacle through which an oxygen-containing gas is bubbled prior to inhalation by a subject, and the invention therefore also relates to receptacles containing the compositions.

公开(公告)号：WO2022072439A1

公开(公告)日：2022-04-07

申请号：PCT/US2021/052571

申请日：2021-09-29

Applicant: LG BIONANO CO. LTD ,  WU, Chien-Chin

Inventor： WU, Chien-Chin

IPC: A61K33/26 ,  A61K47/54 ,  A61P3/02 ,  A61P7/06 ,  A61K47/26 ,  A61K47/36

Abstract: A method of preparing an iron hydroxide product is provided. The method includes the steps of: adding a first base solution to a solution of a ferric salt to obtain Mixture A having a pH value of 2.7-2.8, adding a second base solution to Mixture A to prepare a crude iron hydroxide suspension having a pH value of 2.8-3.8, and adding a third base solution to adjust the pH of the crude iron hydroxide suspension to 5-9, followed by purification and concentration, thereby obtaining a purified polynuclear iron hydroxide suspension containing polynuclear iron hydroxide. Also provided are nano iron complexes, e.g., iron hydroxide carbohydrate complex and their preparation methods.

公开(公告)号：WO2022013744A1

公开(公告)日：2022-01-20

申请号：PCT/IB2021/056301

申请日：2021-07-13

Applicant: ADIFEED SP. Z O. O.

Inventor： ROZANSKI, Henryk ,  IWINSKI, Hubert

IPC: A61K31/19 ,  A61K36/23 ,  A61K33/245 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/38 ,  A61K33/243 ,  A61K33/24 ,  A61P33/02 ,  A61K33/34

Abstract: The subject of invention is a veterinary composition comprising an essential oil, characterised in that the essential oil is selected from the group comprising parsley seed oil, lovage seed oil, celery seed oil, and wherein the said essential oil is present in the form of a complex with a mixture of organic acids comprising four acids selected from the group comprising: valeric acid, isovaleric acid, lactic acid, butyric acid, acetic acid, propionic acid, formic acid, benzoic acid, pelargonic acid, salicylic acid, malonic acid, citric acid, phthalic acid, tartaric acid, oxalic acid, malic acid, shikimic acid, fumaric acid, mandelic acid, cinnamic acid or derivatives thereof and a metal selected from the group comprising iron, bismuth, zinc, copper, manganese, cobalt, molybdenum, chromium, silver, gold, platinum, tungsten, germanium, tin, strontium, antimony, their salts, or oxides thereof, for use in the treatment and/or prevention of diseases caused by protozoa in animals. The invention also relates to a method of manufacturing a veterinary composition for treating and/or preventing protozoan diseases in animals, containing an essential oil according to the invention.

公开(公告)号：WO2021257543A1

公开(公告)日：2021-12-23

申请号：PCT/US2021/037403

申请日：2021-06-15

Applicant: BUILDING BLOCK NUTRITIONALS, LLC

Inventor： MCGRATH, James, W., Jr. ,  MANNING, Paul, B. ,  SCAVOLA, Eugene, R.

IPC: A23L33/00 ,  A61K33/26 ,  A61K38/17 ,  A23L2/395 ,  A23L2/58 ,  A23L2/60 ,  A23L2/66 ,  A23L33/12 ,  A23L33/125 ,  A23L33/155 ,  A23L33/16 ,  A23L33/19 ,  A23L33/40 ,  A23V2002/00 ,  A61K38/38 ,  A61K38/40 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K9/0095 ,  A61P3/02

Abstract: The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride; lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and fructooligo s accharides. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal tract, promoting proper gastrointestinal function, nutrient absorption, proper immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

公开(公告)号：WO2021218004A1

公开(公告)日：2021-11-04

申请号：PCT/CN2020/116031

申请日：2020-09-18

Applicant: 天津大学

Inventor： 常津 ,  窦妍 ,  赵冬菊 ,  唐雨晴

IPC: A61K33/26 ,  A61K9/14 ,  A61P25/28 ,  A61P25/16 ,  A61P25/14 ,  A61P25/08 ,  A61P25/00 ,  A61P25/02

Abstract: 本申请涉及普鲁士蓝纳米颗粒在制备预防、延缓或治疗神经系统退行性疾病药物中的应用。本申请研究发现普鲁士蓝纳米颗粒在预防、延缓或治疗神经系统退行性疾病方面均具有显著的功效。细胞水平试验结果表明，普鲁士蓝纳米颗粒能够降低过氧化氢刺激的神经细胞内的ROS水平，提高过氧化氢刺激的神经细胞中的活细胞比例；动物水平试验结果表明，普鲁士蓝纳米颗粒能够显著降低神经系统退行性疾病模型小鼠海马中氧化应激标志物的表达水平，显著提高神经系统退行性疾病模型小鼠的学习和记忆能力、改善运功功能障碍。且普鲁士蓝纳米颗粒的制备过程简单，易宏量生产，反应条件温和，易表面修饰。

公开(公告)号：WO2021132626A1

公开(公告)日：2021-07-01

申请号：PCT/JP2020/048916

申请日：2020-12-25

Applicant: 国立大学法人北海道大学 ,  ネオファーマジャパン株式会社

Inventor： 迫田　義博 ,  河田　聡史 ,  富岡　基康 ,  吉本　圭一郎 ,  和田　康史

IPC: A61K31/197 ,  A61K33/14 ,  A61K33/24 ,  A61K33/26 ,  A61K33/30 ,  A61K33/34 ,  A61P31/14 ,  A61P43/00

Abstract: 本発明は５－アミノレブリン酸（ＡＬＡ）若しくはその誘導体又はそれらの塩を含む豚熱の治療及び／又は予防剤およびこれを用いた豚熱の治療及び／又は予防方法を提供する。

公开(公告)号：WO2021074159A1

公开(公告)日：2021-04-22

申请号：PCT/EP2020/078794

申请日：2020-10-13

Applicant: JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG

Inventor： HERMANN, Cornelius ,  MEINEL, Lorenz ,  SCHMEHL, Wolfgang ,  POPP, Kevin ,  REILAENDER, Simon

IPC: A61K9/00 ,  A61K9/48 ,  A61K9/51 ,  A61K31/555 ,  A61K33/04 ,  A61K33/24 ,  A61K33/26 ,  A61K33/32 ,  A61K33/40 ,  A61P1/00 ,  A61P1/04 ,  A61P29/02 ,  A01N1/02

Abstract: The present invention discloses a therapeutic gas release system for oral administration comprising a therapeutic gas releasing compound A, and a therapeutic gas release triggering compound B, wherein compound A and B are separated from each other by an inner septum during storage of the system, wherein compound A and B are surrounded by an outer membrane, which is a gas-permeable and water- and solid-impermeable membrane, preferably a silicone membrane, and wherein therapeutic gas release from the system is activated before oral administration by breaking the inner septum. The therapeutic gas released from the system of the present invention is suitable for the treatment of (inflammatory) diseases of the gastrointestinal tract.